<DOC>
	<DOCNO>NCT02549261</DOCNO>
	<brief_summary>Nimotuzumab ( hR3 ) IgG1 humanize monoclonal antibody recognize epitope locate extra cellular domain human epidermal growth factor receptor ( EGFR ) . Clinical efficacy show adult head neck cancer . The study assess efficacy safety combination Nimotuzumab administer concomitantly chemoradiotherapy patient NSCLC .There tolerance trial Nimotuzumab Combination With Radiochemotherapy treatment randomization , double blind , muti-center site trial treatment .</brief_summary>
	<brief_title>Nimotuzumab Combination With Radiochemotherapy Patients With Stage IIIA/IIIB Non-small Cell Lung Cancer</brief_title>
	<detailed_description>There tolerance trial Nimotuzumab Combination With Radiochemotherapy treatment randomization , double blind , muti-center site trial treatment .</detailed_description>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Etoposide phosphate</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Etoposide</mesh_term>
	<criteria>1 . Age 18 70 2. male female 3 . Subjects pathologically cytologically document stage IIIB IV NSCLC . Disease must newly diagnose . 4 . Subjects would refer radical radiation therapy , never previous chemotherapy thoracic radiation therapy . 5 . V20 &lt; 30 % , mean percentage volume lung receive radiation &lt; 20Gy account whole volume lung le 30 % . 6 . Presence least 1 unidimensionally measurable index lesion , long diameter ≥ 20 mm use conventional computer tomography ( CT ) /magnetic resonance imaging ( MRI ) scan ≥ 10 mm use spiral compute tomography scan . 7. without pulmonary atelectasis , malignant pleural effusion malignant hydropericardium . 8. ECOG performance status 02 , Life expectancy 3 month . 9. without malignancy history , except curative carcinoma situ cervix skin basal cell carcinoma . 10. function major organ ( haemogram , heart , liver , kidney ) basically normal , White blood count ≥3.5 x 109/L neutrophil ≥1.5 x 109/L , platelet count≥100 x 109/L , hemoglobin ≥90g/L . Total bilirubin ≤1.5 time upper limit normal ( ULN ) range ; alkaline phosphatase ( ALP ) ≤ 2.5 time ULN , Transaminases AST ( SGOT ) ALT ( SGPT ) ≤ 2.5 time ULN , serum creatinine ≤ 1.2 time ULN . pulmonary function , FEV1≥1L , ＞40 % normal value . 11. willing able comply schedule visit , treatment plan , laboratory test , study procedure . 12. female male patient must use adequate method contraception . 13 . Signature inform consent 1 . Previous radiotherapy , chemotherapy anticancer biotherapy . Participation clinical trial within 1 month prior inclusion trial . 2. measureable lesion lesion could determine . 3 . Severe disease lung , i.e . emphysema , interstitial pneumonia , bronchial asthma . 4. uncontrolled diabetes—random plasma glucose ; RPG＞11.1mmol/L.（RPG &gt; 11.1mmol/L , bloodfasting sugar ; BFS ; &lt; 7.8mmol/L，the patient also enrolled） . 5 . With serious internal disease uncontrolled infection . 6. refractoriness dysentery enterospasm , intestinal obstruction . 7. pregnancy , lactation , fertility use prohibit contraceptive method . 8. cardiovascular disease history , congestive heart failure＞GradeII , New York Heart Association ( NYHA ) criterion ) . With unstable angina , de novo angina ( happen within 3 month prior inclusion trial ) myocardial recently six month . 9 . With drug addition , I.e . , drugtaking , drugtaking long time ; type B hepatitis C hepatitis active stage , AIDS . 10 . With organ transplantation , use adrenocortical hormone immunosuppressive agent long time . 11 . With history serious allergic allergy . 12 . Not fit clinical trial judge investigator .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>September 2015</verification_date>
	<keyword>nimotuzumab</keyword>
	<keyword>non-small cell lung cancer</keyword>
	<keyword>radiochemotherapy</keyword>
	<keyword>stage IIIA/IIIB non-small cell lung cancer</keyword>
</DOC>